Ose Immunotherapeutics
Records under this name other than the patents Ose Immunotherapeutics holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 28 patents it holds.
Showing 1 to 5 of 5 · Back to Ose Immunotherapeutics
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,562,098 | Anti-CD28 Humanized Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 11,365,257 | Methods for Promoting T Cells Response by Administering an Antagonist of Human C-Type Lectin-Like Receptor 1 (CLEC-1) Formerly held In force · High confidence | In force | High confidence | |
| US 12,077,820 | Biomarkers for Assessing the Response Status for Treatment of Inflammatory Condition or Disease Affecting the Digestive Tract Such as Inflammatory Bowel Disease in Human Patients Formerly held In force · High confidence | In force | High confidence | |
| US 12,448,454 | Humanized ANTI-CLEC-1A Antibodies and Antigen-Binding Fragments Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 9,301,955 | Tritoqualine for use in the treatment of cystic fibrosis Lapsed on the fee record Ended Apr 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 5, 2024 | From the USPTO record |